Harbour Investment Management LLC Sells 50 Shares of Becton, Dickinson and Company (NYSE:BDX)

Harbour Investment Management LLC lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,274 shares of the medical instruments supplier’s stock after selling 50 shares during the period. Harbour Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $2,236,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. PineStone Asset Management Inc. grew its holdings in Becton, Dickinson and Company by 141.6% in the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after buying an additional 788,735 shares in the last quarter. M&G Plc acquired a new position in shares of Becton, Dickinson and Company in the first quarter valued at about $173,692,000. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after acquiring an additional 688,296 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Becton, Dickinson and Company by 8.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares in the last quarter. Finally, Magnetar Financial LLC bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $75,493,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BDX shares. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Price Performance

Shares of BDX traded up $1.65 during mid-day trading on Friday, reaching $235.24. The company had a trading volume of 1,278,383 shares, compared to its average volume of 1,371,782. The company has a market capitalization of $67.99 billion, a price-to-earnings ratio of 48.40, a P/E/G ratio of 1.77 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The company’s 50 day simple moving average is $237.56 and its 200 day simple moving average is $235.07. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $259.92.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $2.96 earnings per share. Analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.